T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector.

The progression-free survival (PFS) time was longer in mice that received the combination of Lenti-HPV-07 and anti-TIM3 mAb compared to the mice treated with the Lenti-HPV-07 + Ctrl Ig, even though the difference did not reach statistical significance (Fig. 5e ).

also in 111,027 other papers